基蛋生物(603387) - 2020 Q3 - 季度财报

Important Notice The company's board of directors, supervisory board, and all directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of this quarterly report - The company's responsible person, the person in charge of accounting work, and the head of the accounting department guarantee the truthfulness, accuracy, and completeness of the financial statements in the quarterly report[5] - This company's third-quarter report is unaudited[5] Company Profile This section provides an overview of the company's fundamental information, including key financial data and shareholder structure Key Financial Data In the first three quarters of 2020, operating revenue grew 20.99% to 763 million RMB, while net profit attributable to shareholders slightly decreased 0.88% to 197 million RMB, with operating cash flow increasing 46.77% and total assets growing 20.49% 2020 First Three Quarters Key Financial Data | Indicator | Year-to-Date (Jan-Sep) | Prior Year-to-Date (Jan-Sep) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 762,903,602.56 RMB | 630,555,259.90 RMB | 20.99% | | Net Profit Attributable to Shareholders | 197,122,874.26 RMB | 198,868,020.86 RMB | -0.88% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 176,680,757.42 RMB | 172,132,565.92 RMB | 2.64% | | Net Cash Flow from Operating Activities | 81,699,213.96 RMB | 55,665,345.52 RMB | 46.77% | | Basic Earnings Per Share (RMB/share) | 0.75 | 0.77 | -2.60% | | Indicator | As of Report Period End | As of Prior Year-End | Change (%) | | Total Assets | 2,418,944,330.76 RMB | 2,007,639,351.37 RMB | 20.49% | | Net Assets Attributable to Shareholders | 1,729,578,524.02 RMB | 1,624,972,044.14 RMB | 6.44% | 2020 First Three Quarters Non-recurring Gains and Losses | Item | Year-to-Date Amount (Jan-Sep) | | :--- | :--- | | Gains/Losses from Disposal of Non-current Assets | 470,895.59 RMB | | Government Grants Included in Current Profit/Loss | 12,071,246.22 RMB | | Gains/Losses from Entrusted Investment or Asset Management | 14,577,660.45 RMB | | Other Non-operating Income and Expenses, Net | -3,802,228.53 RMB | | Total | 20,442,116.84 RMB | Shareholder Information As of September 30, 2020, the company had 18,398 shareholders, with controlling shareholder Su Enben holding 39.52% and having related party relationships with Su Enkui and Nanjing Aiji Information Consulting Co., Ltd - As of the end of the reporting period, the company had a total of 18,398 shareholders[8] Top Ten Shareholders' Shareholding | Shareholder Name | Shares Held at Period End | Percentage (%) | | :--- | :--- | :--- | | Su Enben | 102,893,008 | 39.52 | | Nanjing Aiji Information Consulting Co., Ltd. | 11,336,399 | 4.35 | | National Council for Social Security Fund 503 Portfolio | 9,000,045 | 3.46 | | Huatai Zijin (Jiangsu) Equity Investment Fund | 7,454,241 | 2.86 | | Xu Xingde | 5,938,953 | 2.28 | | Hong Kong Securities Clearing Company Limited | 5,642,243 | 2.17 | | Tianjin Jieyuan Asset Management Partnership | 3,764,376 | 1.45 | | Su Enkui | 3,011,501 | 1.16 | | Dongxing Securities Co., Ltd. | 2,885,421 | 1.11 | | Bank of China - China Merchants CSI Bio-Pharmaceutical Index Graded Fund | 2,287,949 | 0.88 | - Explanation of major shareholder related party relationships: Su Enben and Su Enkui are brothers, and Su Enben is the actual controller of Nanjing Aiji Information Consulting Co., Ltd[10] Preferred Shareholder Information The company had no preferred shareholders during the reporting period - The company has no preferred shareholders[11] Significant Events This section details significant events, including major changes in financial statement items, progress of key initiatives, and fulfillment of commitments Analysis of Significant Changes in Key Financial Statement Items and Indicators Significant changes occurred across financial accounts, with accounts receivable up 79.86% due to agency business, construction in progress up 211.92%, short-term borrowings up 211.82%, operating costs up 55.63% from higher-cost agency business, and increased net cash outflow from investing activities due to wealth management product purchases Balance Sheet and Income Statement Major Changes | Account Name | Change Ratio (%) | Primary Reason | | :--- | :--- | :--- | | Accounts Receivable | 79.86% | Increase in terminal hospital payments due to increased agency business | | Construction in Progress | 211.92% | New equipment awaiting installation and expenditures for Phase II factory construction | | Development Expenditures | 578.08% | Increased investment in development expenditures during the reporting period | | Goodwill | 8,348.96% | New consolidation of controlling subsidiary Jingchuan Diagnostics | | Short-term Borrowings | 211.82% | Increased short-term borrowings due to reasonable utilization of bank credit lines | | Operating Costs | 55.63% | Change in revenue structure, with an increase in higher-cost agency business | | Financial Expenses | -362.95% | Combined impact of new loan interest expenses and changes in exchange gains/losses | | Credit Impairment Losses | 124.66% | Increase in accounts receivable led to a corresponding increase in credit impairment losses | Cash Flow Statement Major Changes | Project Name | Change Ratio (%) | Primary Reason | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 46.77% | Increase in sales collections and decrease in taxes paid | | Net Cash Flow from Investing Activities | -470.37% | Increase in amounts paid for wealth management products during the current period | | Net Cash Flow from Financing Activities | -277.77% | Increase in loans obtained during the current period | Progress of Significant Events During the reporting period, the company actively managed idle funds, with 528.15 million RMB in outstanding wealth management products and 12.37 million RMB in cumulative income, and successfully acquired 54.96% of Wuhan Jingchuan Diagnostics Technology Co., Ltd., making it a controlling subsidiary - The company utilized idle self-owned funds not exceeding 1.5 billion RMB for cash management; as of September 30, 2020, the outstanding balance of wealth management products was 528.15 million RMB, generating cumulative income of 12.37 million RMB during the reporting period[16] - The company completed the share acquisition and capital increase of Wuhan Jingchuan Diagnostics Technology Co., Ltd., holding a total of 54.96% of its shares, making Jingchuan Diagnostics a controlling subsidiary[17] Fulfillment of Commitments The company had no overdue unfulfilled commitments during the reporting period - The company had no overdue unfulfilled commitments during the reporting period[19] Performance Forecast The company has not issued any warnings regarding potential cumulative net profit losses or significant changes from the beginning of the year to the end of the next reporting period - The company has not predicted that the cumulative net profit from the beginning of the year to the end of the next reporting period may be a loss or undergo significant changes compared to the same period last year[19] Appendix This section contains the company's financial statements and related disclosures Financial Statements This section provides the company's consolidated and parent company balance sheets, income statements, and cash flow statements as of September 30, 2020 Consolidated Balance Sheet As of September 30, 2020, the company's total assets were 2.42 billion RMB, up 20.49% from the beginning of the year; total liabilities were 534 million RMB, up 63.76%; and equity attributable to parent company owners was 1.73 billion RMB, up 6.44% Company Balance Sheet As of September 30, 2020, the parent company's total assets were 2.09 billion RMB, total liabilities were 415 million RMB, and total owner's equity was 1.67 billion RMB Consolidated Income Statement In the first three quarters of 2020, the company achieved total operating revenue of 763 million RMB, up 20.99%; total operating costs of 534 million RMB, up 25.62%; and net profit attributable to parent company shareholders of 197 million RMB, down 0.88%, with Q3 net profit attributable to parent company shareholders at 101 million RMB, up 124.78% Company Income Statement In the first three quarters of 2020, the parent company achieved operating revenue of 401 million RMB, down 12.39%, and net profit of 136 million RMB, down 36.90% Consolidated Cash Flow Statement In the first three quarters of 2020, net cash flow from operating activities was 81.70 million RMB, up 46.77%; net cash flow from investing activities was -177 million RMB due to increased investment payments; and net cash flow from financing activities was 103 million RMB due to increased borrowings Company Cash Flow Statement In the first three quarters of 2020, the parent company's net cash flow from operating activities was 126 million RMB, up 15.49%; net cash flow from investing activities was -273 million RMB; and net cash flow from financing activities was 67.20 million RMB Explanation of Adjustments for First-Time Adoption of New Standards Effective January 1, 2020, the company adopted new revenue standards, reclassifying advance receipts from 'Advance Receipts' to 'Contract Liabilities,' which only impacts financial statement presentation without affecting opening total assets, total liabilities, or net assets - The company adopted the new revenue standard effective January 1, 2020[47][51] Consolidated Balance Sheet Adjustments | Item | December 31, 2019 | January 1, 2020 | Adjustment Amount | | :--- | :--- | :--- | :--- | | Advance Receipts | 39,686,835.91 RMB | 0 RMB | -39,686,835.91 RMB | | Contract Liabilities | 0 RMB | 39,686,835.91 RMB | 39,686,835.91 RMB | Audit Report This quarterly report is unaudited - This quarterly financial report is unaudited[52]